ResMed faces securities fraud probe after Q4 earnings miss and safety costs hit stock price.

ResMed reported weaker-than-expected Q4 fiscal 2026 results, including lower adjusted gross margins and operating income, partly due to $42 million in expenses related to safety notifications for Astral respirators with leak issues. Following this announcement, ResMed's stock dropped over 5%. Pomerantz LLP is investigating whether ResMed and its executives engaged in securities fraud or unlawful practices, potentially leading to a class action lawsuit. Investors affected are encouraged to contact the law firm for more information.